healthevidencedigest

Tag: immunotherapy

  • A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

    A Historic First: FDA Approves Immunotherapy for Platinum-Resistant Ovarian Cancer — What the KEYNOTE-B96 Data Tells Us

    📌 The essentials On February 10, 2026, the FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (combined positive score, or CPS, of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy. This is the first FDA-approved immunotherapy for ovarian cancer in history. The clinical basis: KEYNOTE-B96/ENGOT-ov65 (NCT05116189), a randomized, double-blind, placebo-controlled Phase 3 trial in 643 patients, showed median overall survival of 18.2 months versus 14.0 months with placebo (HR 0.76; p=0.0053) in the PD-L1 CPS of 1 or higher population. The first statistically significant OS benefit ever demonstrated by an immune checkpoint inhibitor in ovarian cancer. A companion diagnostic requirement: Tumor testing with the PD-L1 IHC 22C3 pharmDx assay confirming CPS of 1 or higher is required before treatment. This is a requirement, not a recommendation.

    Ovarian cancer has resisted immunotherapy for decades. Every major trial of immune checkpoint inhibitors in this disease came back negative or borderline, results that didn’t survive longer follow-up. The field watched other gynecologic cancers, particularly cervical and endometrial, respond to PD-1 blockade while ovarian cancer remained stubbornly outside that story.

    That changed on February 10, 2026.

    The FDA approved pembrolizumab (Keytruda, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS of at least 1). The approval covers patients who have received one or two prior lines of systemic therapy.

    It is the first FDA-approved immunotherapy for ovarian cancer in history.

    This post covers what platinum resistance means and why it matters, what KEYNOTE-B96 showed across its primary and key secondary endpoints, how to read the survival data carefully, what the companion diagnostic approval means in practice, and what questions are still open.

    Platinum Resistance: Why This Setting Is So Hard to Treat

    Most women with advanced ovarian cancer respond well to their first-line treatment, typically surgery followed by platinum-based chemotherapy, often combined with a taxane and increasingly with PARP inhibitors as maintenance. Response rates in the frontline setting can exceed 70 to 80%.

    The problem is recurrence. About 70 to 80% of patients with advanced ovarian cancer relapse after initial treatment. When recurrence happens, the most important prognostic factor is how quickly it occurs after the last platinum therapy. Patients whose disease progresses more than six months after platinum are classified as platinum-sensitive and can be retreated with platinum. Patients whose disease progresses within six months are classified as platinum-resistant.

    Platinum resistance is a watershed moment in the treatment arc. Non-platinum options, including weekly paclitaxel, pegylated liposomal doxorubicin, gemcitabine, and bevacizumab, produce response rates in the 10 to 20% range and median progression-free survival measured in months. Median overall survival in platinum-resistant ovarian cancer has historically ranged from roughly 12 to 16 months. These patients carry significant unmet need, and the disease is hard to control with anything currently available.

    That is the context in which the KEYNOTE-B96 results need to be understood.

    The KEYNOTE-B96 Trial: Design and Patient Population

    KEYNOTE-B96 (also known as ENGOT-ov65, NCT05116189) was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial enrolling 643 patients with histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Eligibility required:

    • Platinum-resistant disease, defined as radiographic progression within six months of the last platinum-based regimen
    • One or two prior lines of systemic therapy for ovarian carcinoma
    • At least one prior platinum-based chemotherapy regimen
    • Measurable disease by RECIST v1.1

    Patients with primary platinum-refractory disease, meaning progression during or immediately after first-line platinum, were excluded.

    Patients were randomized 1:1 to pembrolizumab plus weekly paclitaxel (80 mg/m² on days 1, 8, and 15 of each 3-week cycle), with or without bevacizumab (10 mg/kg every two weeks), or placebo plus the same backbone. Bevacizumab use was at investigator’s discretion and was a stratification factor. Stratification also included geographic region and PD-L1 expression by CPS.

    The primary endpoint was investigator-assessed progression-free survival (PFS) by RECIST v1.1, evaluated first in the PD-L1 CPS of 1 or higher population, then in the ITT population. Overall survival was a key secondary endpoint.

    What is PD-L1 CPS and why does it determine eligibility? PD-L1 Combined Positive Score (CPS) measures PD-L1 protein expression across tumor cells, tumor-associated lymphocytes, and macrophages. A CPS of 1 or higher means at least 1 PD-L1-staining cell per 100 tumor cells was detected. This is a relatively low threshold: in KEYNOTE-B96, approximately 466 of 643 patients (roughly 72%) had CPS of 1 or higher. The FDA approval is restricted to CPS of 1 or higher patients, where both PFS and OS benefits were demonstrated. The ITT population also showed significant PFS improvement, but the OS benefit was most clearly established in the CPS of 1 or higher group. This matters in practice: before receiving this regimen, a patient’s tumor must be tested with the FDA-approved companion diagnostic, the PD-L1 IHC 22C3 pharmDx assay, and return a CPS of 1 or higher result. This is a requirement, not a recommendation.

    The Results: Progression-Free Survival and Overall Survival

    The trial conducted two pre-specified interim analyses. The second (IA2), with a data cutoff of May 5, 2025, was presented at ESMO Congress 2025 in Berlin in October 2025 and formed the basis for the February 2026 FDA approval. Final OS data were subsequently published in The Lancet in April 2026.

    Progression-Free Survival

    In the PD-L1 CPS of 1 or higher population (n=466), median PFS was 8.3 months with pembrolizumab versus 7.2 months with placebo, with a hazard ratio of 0.72 (95% CI 0.58 to 0.89; p=0.0014). The 12-month PFS rate was 35.2% for pembrolizumab versus 22.6% for placebo.

    In the ITT population (all 643 patients), median PFS was 8.3 versus 6.4 months (HR 0.70; 95% CI 0.58 to 0.84; p less than 0.0001), with 12-month PFS rates of 33.1% versus 21.3%.

    These are statistically significant and clinically meaningful improvements in a setting where six months of progression-free survival is often considered a reasonable benchmark.

    Overall Survival

    Among the 466 PD-L1 CPS of 1 or higher patients, median OS was 18.2 months in the pembrolizumab arm versus 14.0 months with placebo, a hazard ratio of 0.76 (95% CI 0.61 to 0.94; p=0.0053). The 12-month OS rate was 69.1% versus 59.3%. The 18-month OS rate was 51.5% versus 38.9%.

    A four-month improvement in median OS. The first statistically significant overall survival benefit ever shown by an immune checkpoint inhibitor in ovarian cancer.

    EndpointPembrolizumab plus chemoPlacebo plus chemoHR (95% CI)P-value
    Median PFS (CPS of 1 or higher)8.3 months7.2 months0.72 (0.58 to 0.89)0.0014
    Median PFS (ITT)8.3 months6.4 months0.70 (0.58 to 0.84)less than 0.0001
    Median OS (CPS of 1 or higher)18.2 months14.0 months0.76 (0.61 to 0.94)0.0053
    12-month OS (CPS of 1 or higher)69.1%59.3%——
    18-month OS (CPS of 1 or higher)51.5%38.9%——

    Source: KEYNOTE-B96/ENGOT-ov65 Phase 3 trial, IA2 (data cutoff May 5, 2025). Final OS data: The Lancet, April 2026. FDA approval: February 10, 2026.

    How to Read These Numbers Carefully

    A four-month improvement in median OS is real and clinically meaningful in this setting, particularly given the historical absence of any survival benefit from immunotherapy in ovarian cancer. But it is worth understanding what the numbers do and don’t tell us.

    The hazard ratio of 0.76 means that at any given point during the trial, patients in the pembrolizumab arm had a 24% lower risk of death than those in the placebo arm. This is not a cure. It is a reduction in the rate of events that translates into prolonged survival for a meaningful portion of patients. The 18-month OS rate shifting from 38.9% to 51.5% is the clearest way to see this: at 18 months, roughly one in eight additional patients were alive in the pembrolizumab arm compared to the placebo arm.

    The approval is restricted to CPS of 1 or higher. About 72% of patients in KEYNOTE-B96 met this threshold, so most platinum-resistant ovarian cancer patients would be eligible for testing, but not all will test positive.

    Median survival describes the midpoint of the distribution, not individual patient outcomes. Some patients in the pembrolizumab arm had substantially longer survival than 18 months. The final OS data from The Lancet publication provides a clearer view of the tail of the survival curve, which will help clarify whether there is a subset of patients with especially durable benefit, the pattern that checkpoint inhibitors sometimes produce in other tumors.

    The Companion Diagnostic: What the PD-L1 Test Means in Practice

    The FDA simultaneously approved the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies) as a companion diagnostic for identifying eligible patients. Tumor PD-L1 testing confirming CPS of 1 or higher is required before treatment, not optional.

    The 22C3 pharmDx assay is the same companion diagnostic used in pembrolizumab approvals across multiple other tumor types, including cervical, endometrial, esophageal, and gastric cancers. At most academic medical centers and major oncology practices, this test is already part of the standard pathology workflow. At community oncology centers or in lower-resource settings, access to and turnaround time on the assay is a practical consideration worth discussing with the treating team.

    Tumor tissue for PD-L1 testing can come from the original diagnosis or a recurrence biopsy. Given that PD-L1 expression can change with disease progression, some oncologists may prefer more recently collected tissue, though the label does not mandate this.

    What about bevacizumab? The approved regimen is pembrolizumab plus paclitaxel, with or without bevacizumab. Bevacizumab (Avastin) is an anti-VEGF antibody with established activity in ovarian cancer, including in the platinum-resistant setting. Its use in KEYNOTE-B96 was at investigator discretion and was a stratification factor. Patients with contraindications to anti-VEGF therapy, such as certain cardiovascular risk factors, recent major surgery, a history of GI perforation, or significant proteinuria, can receive pembrolizumab plus paclitaxel without bevacizumab. Review the full Keytruda prescribing information for complete contraindication guidance.

    Why Previous Immunotherapy Trials in Ovarian Cancer Failed, and Why This One Didn’t

    The history of checkpoint inhibitor trials in ovarian cancer before KEYNOTE-B96 is largely a story of negative results. Earlier Phase 3 trials, including atezolizumab plus chemotherapy in frontline and maintenance settings, did not demonstrate meaningful survival improvements. Single-agent anti-PD-1 trials showed modest response rates of 10 to 15% in unselected ovarian cancer patients.

    Several factors likely contributed. Ovarian cancer has a relatively immunosuppressive tumor microenvironment, with high regulatory T cell infiltration, immunosuppressive cytokines, and ascites fluid that dampens immune activity. Tumor mutational burden is generally lower than in cancers like melanoma or lung cancer that respond robustly to checkpoint inhibitors. And earlier trials often did not select for PD-L1 expression.

    KEYNOTE-B96 made design choices that may have improved its chances. The combination with weekly paclitaxel, a metronomic dosing schedule thought to have immunomodulatory properties alongside its cytotoxic effects, may have made the tumor microenvironment more permissive to immune infiltration. The CPS of 1 or higher selection enriched for a more immunologically accessible population. These are mechanistic hypotheses with biological plausibility, not proven causal explanations, but they provide a rational basis for why this combination in this specific population succeeded where broader efforts did not.

    Safety: What Patients and Clinicians Need to Know

    The safety profile of the pembrolizumab combination in KEYNOTE-B96 was consistent with prior pembrolizumab trials. No new safety signals were identified.

    Pembrolizumab carries immune-mediated adverse reactions as a class, the consequence of broadly activating the immune system. These can affect virtually any organ system.

    Key immune-mediated risks:

    • Pneumonitis: inflammation of the lungs; monitor for new or worsening respiratory symptoms
    • Colitis: diarrhea and abdominal pain; may require corticosteroids or discontinuation
    • Hepatitis: elevated liver enzymes; regular LFT monitoring during treatment
    • Endocrinopathies: thyroid dysfunction, adrenal insufficiency, type 1 diabetes mellitus, hypophysitis
    • Nephritis: elevated creatinine; monitor renal function
    • Dermatologic reactions: rash, rare severe skin reactions including Stevens-Johnson syndrome

    Most immune-mediated adverse reactions are manageable with corticosteroids if caught early. The prescribing information outlines detailed management algorithms, including when to hold versus permanently discontinue pembrolizumab.

    Other warnings:

    Infusion-related reactions: fever, chills, hypotension, and bronchospasm are possible. Standard premedication and monitoring protocols apply.

    Embryo-fetal toxicity: pembrolizumab can cause fetal harm. Women of reproductive potential should use effective contraception during treatment and for at least four months after the final dose.

    Dosing:

    The approved pembrolizumab dose is 200 mg IV every three weeks or 400 mg IV every six weeks, until disease progression, unacceptable toxicity, or up to 24 months of treatment. Pembrolizumab is administered before paclitaxel and bevacizumab when given on the same day.

    Keytruda Qlex, a subcutaneous formulation combining pembrolizumab with berahyaluronidase alfa-pmph, was also approved. The subcutaneous dose is 395 mg/4,800 units every three weeks or 790 mg/9,600 units every six weeks, and can be administered in approximately five to ten minutes rather than the 30-minute IV infusion. For patients receiving multiple cycles over months of treatment, this is a real reduction in clinic time.

    Open Questions and the Road Ahead

    The KEYNOTE-B96 approval opens a new chapter in ovarian cancer treatment, but several clinical questions will shape how the approval is used in practice.

    How durable is the benefit?

    The final OS data in The Lancet provides longer follow-up than the interim analysis. The field will be watching for a favorable tail on the survival curve, the pattern suggesting a subset of patients achieve especially prolonged disease control, which checkpoint inhibitors produce in some tumor types.

    Does PD-L1 CPS fully capture who responds?

    CPS of 1 or higher is a broad threshold. Within the PD-L1-positive population there is likely meaningful heterogeneity in response. Future work will examine whether higher CPS thresholds, tumor mutational burden, microsatellite instability status, or tumor-infiltrating lymphocyte density can further refine patient selection.

    What about earlier lines of therapy?

    The positive KEYNOTE-B96 result will prompt investigators to ask whether pembrolizumab-containing regimens have a role in the frontline or maintenance setting in ovarian cancer. Several trials are already exploring this. The data in those settings will need to be evaluated on their own terms.

    Sequencing after progression on this regimen:

    The approval covers patients after one or two prior regimens. What comes next for patients who progress on pembrolizumab plus chemotherapy? The treatment landscape at third or later lines remains difficult, and ongoing trials will need to address sequencing questions. ClinicalTrials.gov is the primary resource for identifying open studies.

    Project Orbis: A Global Review Pathway This approval was reviewed under Project Orbis, an FDA Oncology Center of Excellence initiative enabling concurrent submission and review across multiple international regulatory agencies. For KEYNOTE-B96, FDA collaborated with Australia’s Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. Project Orbis doesn’t mean all countries approve simultaneously; each agency makes its own decision. But it creates a framework for data sharing that can accelerate global access. The designation signals that review is underway or completed in partner countries.

    What This Means for Patients With Platinum-Resistant Ovarian Cancer

    For patients who have progressed after one or two lines of therapy and are now facing platinum-resistant disease, the conversation with their oncologist includes a genuinely new option for the first time. Pembrolizumab plus paclitaxel, with or without bevacizumab, is not a marginal refinement. It is the first regimen to improve overall survival in this population in a Phase 3 trial.

    The first step is PD-L1 testing. Patients whose disease has not been recently biopsied may want to discuss with their oncologist whether fresh tissue for biomarker testing is feasible and clinically appropriate at the time of progression.

    For related coverage of how immunotherapy and ADC approvals are expanding across gynecologic and breast cancers in 2026, see our posts on Dato-DXd in triple-negative breast cancer, vepdegestrant and the first PROTAC approval in oncology, and what the FDA’s contrasting decisions on camizestrant and vepdegestrant reveal about the future of ESR1-guided treatment.

    Patient advocacy organizations with resources for ovarian cancer include the Ovarian Cancer Research Alliance, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancer. All three maintain clinical trial databases and physician directories. Patients interested in trials evaluating pembrolizumab in earlier-line ovarian cancer settings can search for open studies at ClinicalTrials.gov.

    Sources

    FDA approval: FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma. February 10, 2026. FDA.gov.

    KEYNOTE-B96 trial registration: NCT05116189. ClinicalTrials.gov.

    ESMO 2025 abstract: Colombo N et al. Pembrolizumab vs Placebo Plus Weekly Paclitaxel plus/minus Bevacizumab in Platinum-Resistant Recurrent Ovarian Cancer. LBA3. ESMO Congress 2025, Berlin, October 2025.

    Final OS publication: KEYNOTE-B96/ENGOT-ov65 final overall survival analysis. The Lancet. April 2026.

    Merck press release: Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival. May 2025. merck.com.

    OncLive approval coverage: KEYNOTE-B96 Approval Reinforces the Shift Toward Biomarker-Driven Treatment in Recurrent PROC. OncLive. March 2026.

    Clinical review: The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial. PubMed Central.

    Keytruda prescribing information: Keytruda (pembrolizumab) and Keytruda Qlex Prescribing Information. Merck. 2026.

    Keytruda Qlex FDA approval: FDA approves pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for multiple indications.

    Companion diagnostic: PD-L1 IHC 22C3 pharmDx. FDA list of cleared or approved companion diagnostics.

    Project Orbis: Project Orbis. FDA Oncology Center of Excellence.

    Patient resources: Ovarian Cancer Research Alliance | National Ovarian Cancer Coalition | Foundation for Women’s Cancer | ClinicalTrials.gov

    Disclaimer: Health Evidence Digest provides general health and regulatory information for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Treatment decisions for ovarian cancer should be made in consultation with a board-certified gynecologic oncologist experienced in managing platinum-resistant disease.
  • The FDA Rejected Replimune’s RP1 for Melanoma. Here Is Exactly Why, and What Has to Happen Next.

    The FDA Rejected Replimune’s RP1 for Melanoma. Here Is Exactly Why, and What Has to Happen Next.

    📌 The essentials On April 10, 2026, the FDA issued a Complete Response Letter (CRL) to Replimune for BLA 125827, its application for vusolimogene oderparepvec (RP1, also known as Vusolimogene oderparepvec, brand name RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed on prior PD-1-based therapy. The CRL is not a final rejection. It identifies deficiencies Replimune must address before the application can be reconsidered. The FDA’s concerns are entirely evidentiary, not about safety. The core problem: the pivotal evidence came from a single-arm Phase 2 study (RPL-001-16), which the FDA had previously told Replimune was insufficient to support approval. Without a randomized comparator, the agency could not determine whether observed tumor responses were attributable to RP1, to nivolumab, or to patient-specific factors. The path forward: the FDA requires adequate and well-controlled randomized trials demonstrating RP1’s independent contribution to clinical benefit. Replimune may request a Type A meeting with the FDA to discuss whether modifications to the ongoing IGNYTE-3 Phase 3 trial (NCT05765994) could address the requirements.

    Unresectable melanoma that has progressed after checkpoint inhibitor therapy is one of the hardest clinical scenarios in oncology. PD-1 inhibitors like pembrolizumab and nivolumab transformed the treatment of metastatic melanoma beginning in 2014, extending survival for patients who previously had very limited options. But when melanoma progresses on those drugs, the question of what comes next has no clear answer. The approved options are limited, the responses are modest, and the disease is often aggressive by the time it reaches that stage.

    Vusolimogene oderparepvec (RP1) is an oncolytic herpes simplex virus, an engineered virus designed to selectively infect and kill tumor cells while simultaneously triggering a systemic immune response. It was specifically developed to work in combination with checkpoint inhibitors and showed promising results in early-phase testing. Replimune submitted a Biologics License Application (BLA) based on Phase 2 data in combination with nivolumab.

    On April 10, 2026, the FDA responded with a Complete Response Letter. The decision does not close the door on RP1. It identifies, in specific and instructive detail, exactly what the clinical evidence package was missing and what is required to proceed.

    What Oncolytic Immunotherapy Is and Why RP1 Is Interesting

    To understand what Replimune was trying to do, and why the regulatory challenge is real rather than arbitrary, it helps to understand the mechanism of oncolytic virotherapy.

    Oncolytic viruses are engineered to selectively replicate inside tumor cells, causing them to burst and die, while largely sparing normal tissue. The death of those tumor cells releases antigens and danger signals that can alert the immune system to the presence of cancer. In theory, an oncolytic virus can convert a “cold” tumor, one with low immune infiltration and low response to checkpoint inhibitors, into a “hot” one where the immune system actively attacks the cancer.

    RP1 is engineered from herpes simplex virus type 1 (HSV-1) with two modifications designed to enhance its therapeutic profile: deletion of the ICP34.5 gene to reduce neurovirulence and enhance tumor selectivity, and insertion of a GALV-GP R(-) fusogenic membrane glycoprotein that causes infected cells to fuse with neighboring cells, amplifying tumor cell death and antigen release. This fusogenic enhancement is what distinguishes RP1 from talimogene laherparepvec (T-VEC, Imlygic), the only previously approved oncolytic virus for melanoma, which does not carry this feature.

    RP1 is administered by direct injection into tumor lesions (intratumoral injection). The proposed mechanism of clinical benefit involves both local tumor destruction at injected lesions and systemic immune activation that could, in principle, attack non-injected lesions and metastatic sites. That systemic effect is the central clinical and regulatory question: does injecting a virus into accessible tumors produce meaningful benefit throughout the body, and can a clinical trial reliably detect and attribute that benefit?

    What the RPL-001-16 Trial Showed and Why It Was Not Enough

    The pivotal evidence for the BLA came from RPL-001-16 (NCT03767348), a Phase 2 single-arm study evaluating RP1 plus nivolumab in patients with advanced cutaneous melanoma. The trial enrolled patients whose disease had progressed on prior PD-1 therapy, exactly the patient population with the highest unmet need in this disease.

    In the Phase 2 data, the combination showed an objective response rate that generated initial enthusiasm in the oncology community. However, the FDA’s concern was not primarily about the magnitude of the responses. It was about whether the study design allowed any reliable conclusion about what caused them.

    The FDA had communicated to Replimune prior to BLA submission that a single-arm trial in this combination setting was insufficient to demonstrate RP1’s contribution to clinical benefit. Replimune proceeded with the BLA nonetheless, apparently believing the strength of the data could overcome the design limitation.

    It could not.

    Why the FDA Issued the CRL: Four Specific Problems

    1. The study design could not isolate RP1’s contribution

    The fundamental problem with a single-arm trial combining RP1 with nivolumab is that nivolumab has established activity in melanoma. When a trial shows responses in patients receiving a known-active drug plus a new drug, with no control arm receiving the known-active drug alone, it is impossible to determine how much of the response came from the new drug. The FDA had been explicit that this design flaw was fatal to the application before it was submitted. A randomized trial comparing RP1 plus nivolumab versus nivolumab alone would allow direct attribution of incremental benefit to RP1.

    2. The study population was too heterogeneous

    Patients enrolled in RPL-001-16 varied substantially in prior treatments received, disease burden, lesion characteristics, and performance status. This variability made any cross-trial comparison unreliable and prevented meaningful benchmarking against external data. When a study is highly heterogeneous in ways not controlled by randomization, the results reflect the characteristics of who happened to be enrolled as much as the effects of the drug being studied.

    3. Response assessments were uncertain and potentially confounded

    The FDA identified multiple specific methodological issues that could artificially inflate the observed response rate:

    Non-injected lesion problem: Many patients who showed an overall response did not have measurable non-injected target lesions. Since RP1 is injected directly into accessible tumors, any responses in those directly injected lesions could reflect local tumor destruction by the virus rather than systemic immune activation. If the drug’s value lies in producing systemic benefit beyond the injection site, the evidence needs to show response in tumors the drug never touched. In many cases, it could not.

    Re-injection timing: Some patients received additional RP1 injections after new or enlarging lesions appeared. Under standard RECIST response criteria, new lesions or tumor enlargement typically counts as progression. Injecting the drug into new lesions and then observing their shrinkage can look like a response while obscuring what is actually a progressive disease pattern.

    Surgical excisions and biopsies: Several patients underwent surgical removal or biopsy of lesions during the trial. These procedures can reduce measurable tumor burden in ways that are indistinguishable from drug-induced tumor shrinkage on imaging, inflating apparent response rates.

    Local rather than central pathology review: Response assessments were performed by local investigators rather than a blinded central review committee. Local review is more susceptible to unconscious bias and inconsistency in applying response criteria than independent centralized review.

    These factors collectively undermined the reliability of the reported objective response rate and duration of response as measures of true drug effect.

    4. Supplemental data from the RP1-104 study were insufficient

    Replimune attempted to support the BLA with additional data from an ongoing randomized Phase 2/3 study (RP1-104). However, the FDA found that only a small fraction of the planned study population had been treated at the time of submission, the data lacked independent review, the duration of response data were immature, and there was no prespecified statistical plan for the progression-free survival endpoint. The FDA concluded that these early, exploratory findings from RP1-104 could not compensate for the fundamental deficiencies in the pivotal RPL-001-16 study.

    What the Field of Oncolytic Immunotherapy Needs to Learn From This

    The RP1 CRL is instructive beyond Replimune specifically. It articulates the evidentiary standards the FDA will apply to intratumoral therapies combined with checkpoint inhibitors, and those standards were not invented for this application. They reflect well-established principles of clinical trial design.

    Single-arm trials cannot isolate combination drug contributions. When a novel therapy is combined with an agent that already has proven activity in the indication, a randomized trial with an appropriate comparator arm is not optional. This principle applies across oncology, not just to oncolytic viruses.

    Intratumoral therapies must demonstrate systemic activity. The clinical value proposition of an oncolytic virus is not that it kills directly injected tumors. Surgery can do that. The value proposition is that it triggers systemic immune responses that benefit the whole patient. Evidence of that systemic benefit requires trial designs that can detect and attribute responses in non-injected disease sites.

    Methodological details matter enormously in solid tumor oncology. Re-injection timing, lesion selection for target measurement, the role of concurrent procedures, and the choice of central versus local review are not administrative details. They are scientifically material choices that determine whether a response rate number means what it appears to mean.

    The FDA’s prior communications are not suggestions. Replimune knew before submitting its BLA that the agency had reservations about the single-arm design. Proceeding without addressing that concern was a high-risk regulatory strategy that did not succeed. The FDA’s pre-BLA communications and Type B meetings are the appropriate time to reach agreement on whether an evidentiary package is sufficient.

    The Path Forward: IGNYTE-3

    Replimune has an ongoing Phase 3 trial that may ultimately provide the evidence the FDA requires. The IGNYTE-3 trial (NCT05765994) is a randomized, controlled study designed specifically to address the gap identified in RPL-001-16. The FDA has indicated that Replimune may request a meeting to discuss whether modifications to IGNYTE-3 or additional studies could meet the requirements outlined in the CRL.

    What that trial will need to show, based on the CRL’s specific feedback, is a clear, independently reviewed, randomized demonstration that the combination of RP1 plus nivolumab produces greater clinical benefit than nivolumab alone in patients with unresectable advanced melanoma that has progressed on prior PD-1 therapy. The primary endpoint will need to capture systemic activity, not just responses at injected sites, and the trial design will need to prevent the confounding issues that undermined RPL-001-16.

    The timeline for such a result is measured in years, not months. Until IGNYTE-3 or another adequate study reports, RP1 remains investigational for this indication.

    What This Means for Patients With Advanced Melanoma

    For patients with unresectable melanoma that has progressed on PD-1 therapy, RP1 is not currently an approved treatment option. The CRL means it will remain investigational until adequate trial evidence is generated and reviewed.

    The approved options for melanoma after progression on PD-1 therapy are limited and depend on individual patient factors including BRAF mutation status, prior treatment history, and performance status. Current options include:

    For patients with unresectable advanced melanoma, especially those who have progressed on checkpoint inhibitor therapy, clinical trial enrollment is not a last resort. It is often the best option to access novel therapies in development. The IGNYTE-3 trial may have open enrollment sites. Additional clinical trial options can be searched at ClinicalTrials.gov.

    The Melanoma Research Foundation and the Skin Cancer Foundation both maintain current information on melanoma treatment options and clinical trial resources.

    For related coverage of how the FDA evaluates clinical evidence and what happens when that evidence is found insufficient, see our post on the camizestrant ODAC vote and what it reveals about ctDNA-guided treatment strategies and our analysis of pembrolizumab becoming the first approved immunotherapy for ovarian cancer to understand what a successful immunotherapy approval requires.

    Sources

    Complete Response Letter (primary source): CRL BLA125827 April 10, 2026. open.fda.gov.

    Replimune press release: Replimune Announces Receipt of Complete Response Letter from FDA for RP1 (Vusolimogene Oderparepvec) BLA. Replimune. April 2026.

    IGNYTE-3 Phase 3 trial: NCT05765994. ClinicalTrials.gov.

    RPL-001-16 Phase 2 trial: NCT03767348. ClinicalTrials.gov.

    Oncolytic virus immunotherapy review: Oncolytic Viruses: A New Class of Immunotherapy Agents. PMC8709598.

    T-VEC FDA approval: FDA approves talimogene laherparepvec for melanoma. FDA.gov.

    Nivolumab melanoma approval: FDA approves nivolumab for melanoma. FDA.gov.

    RECIST criteria: New Response Evaluation Criteria in Solid Tumours (RECIST). PMC3107543.

    PD-1 inhibitors overview: Checkpoint Inhibitors. StatPearls. NCBI.

    Complete Response Letter explained: Complete Response Letter. FDA.gov.

    NCCN melanoma guidelines: Melanoma Cutaneous: Clinical Practice Guidelines. NCCN.

    BRAF inhibitors: BRAF Inhibitors. cancer.gov.

    Melanoma cancer overview: Advanced Melanoma Treatment. American Cancer Society.

    Patient resources: Melanoma Research Foundation | Skin Cancer Foundation | ClinicalTrials.gov: melanoma oncolytic

    Disclaimer: Health Evidence Digest provides general information about FDA regulatory actions and health research for educational purposes. This content is not a substitute for professional medical advice. RP1 (vusolimogene oderparepvec) is not currently FDA-approved for any indication. Treatment decisions for advanced or metastatic melanoma should be made in consultation with a qualified oncologist experienced in melanoma and immunotherapy.